<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1870-7203</journal-id>
<journal-title><![CDATA[Acta médica Grupo Ángeles]]></journal-title>
<abbrev-journal-title><![CDATA[Acta méd. Grupo Ángeles]]></abbrev-journal-title>
<issn>1870-7203</issn>
<publisher>
<publisher-name><![CDATA[Grupo Ángeles, Servicios de Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1870-72032018000100041</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tapentadol, un nuevo horizonte en el tratamiento de la neuropatía diabética periférica dolorosa]]></article-title>
<article-title xml:lang="en"><![CDATA[Tapentadol, a new horizon in the treatment of diabetic peripheral painful neuropathy. Review of literature]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bueno Arias]]></surname>
<given-names><![CDATA[Guadalupe Margarita]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jiménez Medina]]></surname>
<given-names><![CDATA[Verania]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[German Córdoba]]></surname>
<given-names><![CDATA[Idaleyvis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lazarini Ruíz]]></surname>
<given-names><![CDATA[José Fernando]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Galindo Soto]]></surname>
<given-names><![CDATA[Judith Isabel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Ángeles Mocel  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Ángeles Mocel  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Ángeles Mocel  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Ángeles Mocel  ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2018</year>
</pub-date>
<volume>16</volume>
<numero>1</numero>
<fpage>41</fpage>
<lpage>46</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1870-72032018000100041&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1870-72032018000100041&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1870-72032018000100041&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: La prevalencia de diabetes mellitus va en aumento y las complicaciones son cada vez más frecuentes, una de las más comunes es la neuropatía diabética periférica que se presenta de 30 a 50% en los pacientes; de 10 a 20% de éstos manifiestan dolor. El mecanismo por el cual se manifiesta el dolor no está claro, pero se ha asociado a estados crónicos de hiperglucemia y factores de riesgo cardiovascular. El dolor que se asocia a este padecimiento es crónico y difícil de manejar, aumenta la morbilidad y mortalidad, así como los costos en la salud. Hay estudios que indican que los opiáceos son los medicamentos más prescritos para el manejo del dolor crónico de este padecimiento, pero por sus efectos adversos los pacientes no se apegan al tratamiento, provocando su suspensión. Gracias a su doble acción el tapentadol, recientemente aprobado por la FDA para el manejo del dolor de la neuropatía diabética periférica, brinda un manejo eficaz del dolor, con disminución de los efectos adversos que se presentan comúnmente con los opioides. Es bien tolerado por los adultos mayores y no se ajusta en pacientes con enfermedad renal moderada o enfermedad hepática leve.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: The prevalence diabetes mellitus is increasing and complications are becoming more frequent, one of the most common complications, is peripheral diabetic neuropathy, which occurs in 30 to 50% of patients; of these, 10 to 20% have pain. The mechanism by which the pain is presented is not well established, but has been associated with chronic conditions of hyperglycemia, and cardiovascular risk factors. The pain associated with this condition is chronic and difficult to manage, increasing morbidity and mortality, as well as health costs. There are studies that demonstrate that opiates are the most prescribed medications for the management of chronic pain of this disease, but because of their adverse effects, patients do not have good attachment to the treatment, causing the suspension of this. Tapentadol, recently approved by the FDA for the management of pain of peripheral diabetic neuropathy; causes by its double action an effective management of the pain, with diminished of the adverse effects that are presented commonly with opioids. It is well tolerated by the elderly and patients with moderate kidney disease or mild liver disease.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Tapentadol]]></kwd>
<kwd lng="es"><![CDATA[neuropatía diabética]]></kwd>
<kwd lng="es"><![CDATA[neuralgia]]></kwd>
<kwd lng="es"><![CDATA[analgésicos opioides]]></kwd>
<kwd lng="es"><![CDATA[inhibidores de la captación de neurotransmisores]]></kwd>
<kwd lng="en"><![CDATA[Tapentadol]]></kwd>
<kwd lng="en"><![CDATA[diabetic neuropathy]]></kwd>
<kwd lng="en"><![CDATA[neuralgia]]></kwd>
<kwd lng="en"><![CDATA[analgesics opioid]]></kwd>
<kwd lng="en"><![CDATA[neurotransmitter uptake inhibitors]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aslam]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rajbhandari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of painful diabetic neuropathy using the self-completed Leeds assessment of neuropathic symptoms and signs questionnaire in a population with diabetes]]></article-title>
<source><![CDATA[Can J Diabetes]]></source>
<year>2015</year>
<volume>39</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>285-95</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Games]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hutchison]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tapentadol-ER for the treatment of diabetic peripheral neuropathy]]></article-title>
<source><![CDATA[Consult Pharm]]></source>
<year>2013</year>
<volume>28</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>672-5</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Desai]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Freeman]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Hung]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Knapp]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Breunig]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical value of tapentadol extended-release in painful diabetic peripheral neuropathy]]></article-title>
<source><![CDATA[Expert Rev Clin Pharmacol]]></source>
<year>2014</year>
<volume>7</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>203-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sadosky]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mardekian]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Parsons]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hopps]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bienen]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Markman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Healthcare utilization and costs in diabetes relative to the clinical spectrum of painful diabetic peripheral neuropathy]]></article-title>
<source><![CDATA[J Diabetes Complications]]></source>
<year>2015</year>
<volume>29</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>212-7</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vinik]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical practice Diabetic sensory and motor neuropathy]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>374</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>1455-64</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Serrano-Atero]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Peramo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cañas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[García-Saura]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Serrano-Álvarez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Caballero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Modulación descendente de la información nociceptiva (I)]]></article-title>
<source><![CDATA[Rev Soc Esp Dolor]]></source>
<year>2002</year>
<volume>9</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>382-90</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Snyder]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gibbs]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Lindsay]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treating painful diabetic peripheral neuropathy an update]]></article-title>
<source><![CDATA[Am Fam Physician]]></source>
<year>2016</year>
<volume>94</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>227-34</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hartemann]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Attal]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bouhassira]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Dumont]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Gin]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Jeanne]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Painful diabetic neuropathy diagnosis and management]]></article-title>
<source><![CDATA[Diabetes Metab]]></source>
<year>2011</year>
<volume>37</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>377-88</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kress]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tapentadol and its two mechanisms of action is there a new pharmacological class of centrally-acting analgesics on the horizon?]]></article-title>
<source><![CDATA[Eur J Pain]]></source>
<year>2010</year>
<volume>14</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>781-3</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wade]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
<name>
<surname><![CDATA[Spruill]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tapentadol hydrochloride a centrally acting oral analgesic]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year>2009</year>
<volume>31</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2804-18</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silverman]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Candiotti]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Gitlin]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tapentadol extended-release a recent addition to our analgesic armamentarium]]></article-title>
<source><![CDATA[Pain Manag]]></source>
<year>2012</year>
<volume>2</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>451-6</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Christoph]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[De Vry]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tzschentke]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain]]></article-title>
<source><![CDATA[Neurosci Lett]]></source>
<year>2010</year>
<volume>470</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>91-4</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Terlinden]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ossig]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fliegert]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lange]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Göhler]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects]]></article-title>
<source><![CDATA[Eur J Drug Metab Pharmacokinet]]></source>
<year>2007</year>
<volume>32</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>163-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Afilalo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Morlion]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of tapentadol ER for managing moderate to severe chronic pain]]></article-title>
<source><![CDATA[Pain Physician]]></source>
<year>2013</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>27-40</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strick]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of severe chronic pain with tapentadol prolonged release - long-term data from pain specialists]]></article-title>
<source><![CDATA[Curr Med Res Opin]]></source>
<year>2014</year>
<volume>30</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2085-92</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baron]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Martin-Mola]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dubois]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Falke]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Steigerwald]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness and safety of tapentadol prolonged release (PR) versus a combination of tapentadol PR and pregabalin for the management of severe, chronic low back pain with a neuropathic component a randomized, double-blind, phase 3b study]]></article-title>
<source><![CDATA[Pain Pract]]></source>
<year>2015</year>
<volume>15</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>455-70</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Etropolski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lange]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Goldberg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Steup]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rauschkolb]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A pooled analysis of patient-specific factors and efficacy and tolerability of tapentadol extended release treatment for moderate to severe chronic pain]]></article-title>
<source><![CDATA[J Opioid Manag]]></source>
<year>2013</year>
<volume>9</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>343-56</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Macedo]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Nailor]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Focus on tapentadol role in the treatment of neuropathic pain]]></article-title>
<source><![CDATA[Formulary]]></source>
<year>2013</year>
<volume>48</volume>
<page-range>395-402</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez Del Águila]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Schenk]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kern]]></surname>
<given-names><![CDATA[KU]]></given-names>
</name>
<name>
<surname><![CDATA[Drost]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Steigerwald]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year>2015</year>
<volume>37</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>94-113</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mehra]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Merchant]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Potluri]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diabetic peripheral neuropathy resource utilization and burden of illness]]></article-title>
<source><![CDATA[J Med Econ]]></source>
<year>2014</year>
<volume>17</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>637-45</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Etropolski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Shapiro]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
<name>
<surname><![CDATA[Okamoto]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lange]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Haeussler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy results of a randomized-withdrawal, placebo-controlled trial]]></article-title>
<source><![CDATA[Curr Med Res Opin]]></source>
<year>2011</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>151-62</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kneip]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Terlinden]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Beier]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes]]></article-title>
<source><![CDATA[Drug Metab Lett]]></source>
<year>2008</year>
<volume>2</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>67-75</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Biondi]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Xiang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Etropolski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Moskovitz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tolerability and efficacy of tapentadol extended release in elderly patients = 75 years of age with chronic osteoarthritis knee or low back pain]]></article-title>
<source><![CDATA[J Opioid Manag]]></source>
<year>2015</year>
<volume>11</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>393-403</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Veal]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Peterson]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pain in the frail or elderly patient does tapentadol have a role?]]></article-title>
<source><![CDATA[Drugs Aging]]></source>
<year>2015</year>
<volume>32</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>419-26</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Christoph]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[De Vry]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schiene]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Tallarida]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Tzschentke]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain]]></article-title>
<source><![CDATA[Eur J Pharmacol]]></source>
<year>2011</year>
<volume>666</volume>
<numero>1-3</numero>
<issue>1-3</issue>
<page-range>72-9</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Giorgi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tramadol and tapentadol hydrochloride an old and a novel atypical opioid drug. An overview on their present applications]]></article-title>
<source><![CDATA[Med Weter]]></source>
<year>2012</year>
<volume>68</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>643-6</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raffa]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Buschmann]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Christoph]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Eichenbaum]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Englberger]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Flores]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanistic and functional differentiation of tapentadol and tramadol]]></article-title>
<source><![CDATA[Expert Opin Pharmacother]]></source>
<year>2012</year>
<volume>13</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1437-49</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Candiotti]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Gitlin]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain tapentadol, a step toward a solution?]]></article-title>
<source><![CDATA[Curr Med Res Opin]]></source>
<year>2010</year>
<volume>26</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1677-84</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cepeda]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Fife]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone results from a cohort study]]></article-title>
<source><![CDATA[J Pain]]></source>
<year>2013</year>
<volume>14</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1227-41</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
